You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

165 search results for: type 2 inflammation

UCARE <b>2</b>0<b>2</b>3: CSU – The Brazil Perspective
expert video

UCARE 2023: CSU – The Brazil Perspective

Dermatology
Dr. Ensina guides discussions on the perspective of CSU management in Brazil.
View more
Managing the Risk of Fibrostenosis in EoE
expert video

Managing the Risk of Fibrostenosis in EoE

Gastroenterology
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.
View more
UCARE <b>2</b>0<b>2</b>3: Non-Histaminergic Neuronal Sensitization in CSU
expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

Dermatology
Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.
View more
EAACI <b>2</b>0<b>2</b><b>2</b> | Hard to Swallow: Identifying and Managing EoE in the Allergy Clinic
expert video

EAACI 2022 | Hard to Swallow: Identifying and Managing EoE in the Allergy Clinic

Gastroenterology
Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.
View more
Skin Dysbiosis in AD
expert video

Skin Dysbiosis in AD

Dermatology
Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Dermatology
Highlights from the ESPD 2023 ADVENT symposium, exploring burden, skin barrier normalization, and current treatments for pediatric atopic dermatitis.
View more
Early Intervention in AD: Latest Clinical and Real-world Data
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Dermatology
Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.
View more
ERS <b>2</b>0<b>2</b>4 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: EcuadorChange country/region